Evidence mapPaperPMID 37583410Full record

ArticleIndian journal of endocrinology and metabolism

A Pilot Study to Assess Effect of Metformin Therapy on Prevention of Double Diabetes in Indian Adolescents with Type-1 Diabetes.

Chirantap Oza, Shruti Mondkar, Nikhil Shah, Chidvilas More, Vaman Khadilkar, Anuradha Khadilkar

Open access · diamondAbstract read
In one paragraph

Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Double Trouble.Indian journal of endocrinology and metabolism
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Chirantap OzaDepartment of Growth and Pediatric Endocrinology, Cowasji Jehangir Medical Research Institute, Pune, Maharashtra, India.
Shruti MondkarDepartment of Growth and Pediatric Endocrinology, Cowasji Jehangir Medical Research Institute, Pune, Maharashtra, India.
Nikhil ShahDepartment of Growth and Pediatric Endocrinology, Cowasji Jehangir Medical Research Institute, Pune, Maharashtra, India.
Chidvilas MoreDepartment of Growth and Pediatric Endocrinology, Cowasji Jehangir Medical Research Institute, Pune, Maharashtra, India.
Vaman KhadilkarDepartment of Health Sciences, Savitribai Phule Pune University, Pune, Maharashtra, India.
Anuradha KhadilkarDepartment of Growth and Pediatric Endocrinology, Cowasji Jehangir Medical Research Institute, Pune, Maharashtra, India.
Jehangir Hospital · INCloudnine · INSavitribai Phule Pune University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Increased prevalence of metabolic syndrome in Indian adolescents owing to the obesity epidemic leads to double diabetes (DD), which is associated with an increased risk of complications in type-1 diabetes (T1D). Metformin may be a useful intervention for the prevention and treatment of insulin resistance in T1D. We conducted this pilot randomized controlled trial with the objective of investigating the effect of metformin on insulin sensitivity in Indian adolescents with T1D. Method: This pilot randomized controlled trial was performed on 59 participants with T1D aged 10-19 years distributed uniformly by gender and puberty across two groups with a 3-month intervention period. The intervention group received metformin (weight less than 60 kg received 500 mg twice daily and more than 60 kg received 1 gm twice daily) and non-metformin group received standard of care for diabetes. Anthropometric, clinical details, biochemistry and insulin sensitivity indices (ISI) were evaluated using standard protocols at baseline and endline. Result: 22.2% of subjects from non-metformin group and 12.5% from metformin group were at the risk of the development of DD. The odds ratio and relative risk for the development of DD in non-metformin subjects were 2.0 and 1.4, respectively, as compared to participants in metformin group. The mean improvement in ISI ranged from 1.4% to 4.6% in participants on metformin as opposed to deterioration of -2% to -14.1% in non-metformin group. On performing the paired sample t-test, the reduction in ISI in non-metformin group was significant. Conclusion: Metformin may prevent deterioration in insulin sensitivity in Indian adolescents with T1D.

Indexed as

Adolescentsdouble diabetesinsulin sensitivitymetabolic syndromemetformintype-1 diabetes

Identifiers

PMID37583410
PMCPMC10424107
OpenAlexW4382137893

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.